Novel N-heterocyclic ylideneamine gold(i) complexes: Synthesis, characterisation and screening for antitumour and antimalarial activity

dc.contributor.authorCoetzee J.
dc.contributor.authorCronje S.
dc.contributor.authorDobrzanska L.
dc.contributor.authorRaubenheimer H.G.
dc.contributor.authorJoone G.
dc.contributor.authorNell M.J.
dc.contributor.authorHoppe H.C.
dc.date.accessioned2011-05-15T15:59:05Z
dc.date.available2011-05-15T15:59:05Z
dc.date.issued2011
dc.description.abstractYlideneamine functionalised heterocyclic ligands, 1,3-dimethyl-1,3-dihydro- benzimidazol-2-ylideneamine (I), 3-methyl-3H-benzothiazol-2-ylideneamine (II) or 3,4-dimethyl-3H-thiazol-2-ylideneamine (III), were employed in the preparation of a series of both charged and neutral gold(i) complexes consisting either of a Au(C6F5) fragment (1-3), a [Au(PPh3)] + unit (4-6) or a [Au(NHC)]+ unit (7) coordinated to the imine nitrogen of the neutral ylideneamine ligand. These complexes were fully characterised by various techniques including X-ray diffraction. In addition, the antitumour and antimalarial potential of selected compounds were assessed in a preliminary study aimed at determining the medicinal value of such compounds. Complexation of the azol-2-ylideneamine ligands with [Au(PPh3)] + increases their antitumour as well as antimalarial activity. © 2011 The Royal Society of Chemistry.
dc.description.versionArticle
dc.identifier.citationDalton Transactions
dc.identifier.citation40
dc.identifier.citation7
dc.identifier.issn14779226
dc.identifier.other10.1039/c0dt01312a
dc.identifier.urihttp://hdl.handle.net/10019.1/10993
dc.subjectAntimalarial activity
dc.subjectCharacterisation
dc.subjectHeterocyclic ligands
dc.subjectN-heterocyclic
dc.subjectLigands
dc.subjectOrganic compounds
dc.subjectSynthesis (chemical)
dc.subjectX ray diffraction
dc.subjectGold compounds
dc.titleNovel N-heterocyclic ylideneamine gold(i) complexes: Synthesis, characterisation and screening for antitumour and antimalarial activity
dc.typeArticle
Files